Results 71 to 80 of about 6,378,886 (285)

An Interview with Geraldine Keams [PDF]

open access: yes, 1987
When Geraldine Keams visited Iowa State University for the annual Symposium on the American Indian in 1983, I had the opportunity to interview her. The tape remained untranscribed until we met again in California during the fall of 1986, more than three ...
Bataille, Gretchen M.
core   +1 more source

Letter on “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Raveena Vij   +2 more
wiley   +1 more source

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich   +10 more
wiley   +1 more source

An Interview About an Illness [PDF]

open access: yes, 2009
The respondent tells of his experience of a life-threatening illness.The fifty one audio and nine video files in this collection include: villages’ life stories, circle-dancing songs and performance, local history, folk tales, and interviews from ...
G.yu lha
core  

Reply to Letter: “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Yana Said   +2 more
wiley   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini   +13 more
wiley   +1 more source

An Interview About Inexplicable Sounds [PDF]

open access: yes, 2009
The respondent tells his experience of hearing strange, inexplicable sounds while riding his motorcycle near a place where many people had previously died in traffic accidents.The fifty one audio and nine video files in this collection include ...
G.yu lha
core  

A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Neurodegeneration with brain iron accumulation (NBIA) comprises a genetically and clinically heterogeneous group of rare neurological disorders characterized particularly by iron accumulation in the basal ganglia. To date, 15 genes have been associated with NBIA.
Seda Susgun   +95 more
wiley   +1 more source

Clinical Characteristics and Outcomes of Early‐Onset Versus Late‐Onset LGI1‐Antibody Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Leucine‐rich glioma‐inactivated 1 antibody (LGI1‐Ab) encephalitis predominantly affected older individuals, but has also been reported in younger patients. However, the demographic, clinical, and prognostic characteristics of early‐onset LGI1‐Ab encephalitis have yet to be systematically elucidated. This study aims to systematically
Yu Kong   +7 more
wiley   +1 more source

Interview mit Thorben Albrecht - Die SPD setzt auf Beteiligung [PDF]

open access: bronze, 2011
Interview Mit   +2 more
openalex   +1 more source

Home - About - Disclaimer - Privacy